<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357133</url>
  </required_header>
  <id_info>
    <org_study_id>2017032</org_study_id>
    <nct_id>NCT03357133</nct_id>
  </id_info>
  <brief_title>Tirofiban for Patients Treated With Alteplase</brief_title>
  <acronym>MR TEA</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Early Administration of Tirofiban in Acute Ischemic Stroke Patients Treated With Intravenous Alteplase Thrombolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after&#xD;
      initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the&#xD;
      effects of administration of tirofiban in acute ischemic stroke patients treated with&#xD;
      intravenous alteplase thrombolysis with alteplase alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The number and speed of enrollment were significantly less than expected.&#xD;
  </why_stopped>
  <start_date type="Actual">December 16, 2017</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of favorable outcome</measure>
    <time_frame>90 days</time_frame>
    <description>favorable outcome was defined as a score of 0, or 1 on the modified Rankin scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS ≤2</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS score</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deterioration after improvement</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct size</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>7 days or discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Severe systemic bleeding</measure>
    <time_frame>7 days or discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stroke-related death</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death form any cause</measure>
    <time_frame>90 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tirofiban and alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban</intervention_name>
    <description>Tirofiban Injection after the alteplase intravenous thrombolysis</description>
    <arm_group_label>Tirofiban and alteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>Only alteplase intravenous thrombolysis</description>
    <arm_group_label>Alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Ischemic stroke symptom with onset ≤4.5 hours treated with IV rt-PA according with&#xD;
             local guidelines.&#xD;
&#xD;
          -  6≤ NIHSS ≤20 before IV tPA, or NIHSS &gt;20 but decrease ≥ 8 after IV rt-PA.&#xD;
&#xD;
          -  ≥ 4 point total NIHSS or ≥ 2 point in one NIHSS category during and after the IV rt-PA&#xD;
             compared to immediately before worsening, an emergency CT scan should be performed to&#xD;
             exclude intracranial hemorrhage&#xD;
&#xD;
          -  Patients or their legally acceptable representative agreed to the treatment and signed&#xD;
             the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whom the treating physician is planning to treat with mechanical thrombectomy&#xD;
             or other endovascular procedure (e.g. Intra-arterial thrombolysis) according with&#xD;
             local guidelines.&#xD;
&#xD;
          -  Patients had used antiplatelet therapy in the past 5 days before the stroke.&#xD;
&#xD;
          -  Patients had used anticoagulant therapy in the past 5 days before the stroke.&#xD;
&#xD;
          -  Scheduled for surgery or interventional treatment requiring study drug cessation.&#xD;
&#xD;
          -  CT scan finding of hypoattenuation involving ≥1/3 of the MCA territory.&#xD;
&#xD;
          -  Any evidence of clinically significant bleeding ,or known coagulopathy.&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance rate &lt;30ml/min)&#xD;
&#xD;
          -  Hepatic dysfunction (ALT &gt;2 folds of Upper limit of normal value or AST&gt;2 folds of&#xD;
             Upper limit of normal value).&#xD;
&#xD;
          -  Pre-existing disability with ≥ mRS 2.&#xD;
&#xD;
          -  Known allergic to tirofiban or other glycoprotein IIb/IIIa antagonist.&#xD;
&#xD;
          -  Severe non-cerebrovascular disease with life expectancy &lt;3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Suzhou Municipal Hoapital</name>
      <address>
        <city>Suzhou</city>
        <state>An Hui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Luohe City</name>
      <address>
        <city>Luohe</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzhou People's Hospital</name>
      <address>
        <city>Luzhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangtan Central Hospital</name>
      <address>
        <city>Xiangtan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

